Extracellular potassium ion (K+)

Extracellular potassium ions in the gastrointestinal lumen represent a critical therapeutic target for the management of hyperkalemia, particularly in patients with impaired renal function or those receiving renin-angiotensin-aldosterone system (RAAS) inhibitor therapy [1][4]. While the kidneys are the primary route for potassium elimination, the gastrointestinal tract provides an alternative pathway for excretion that can be pharmacologically exploited [3]. Potassium binders, such as patiromer and sodium zirconium cyclosilicate, are non-absorbed agents that traverse the gut and utilize cation exchange mechanisms to sequester potassium ions [2][5]. By binding potassium in the lumen and preventing its absorption into the systemic circulation, these agents increase fecal potassium loss and effectively lower serum potassium levels [1][6]. This therapeutic approach is essential for mitigating the risk of life-threatening cardiac arrhythmias associated with high potassium levels while allowing for the continuation of cardioprotective medications [4].

Other names

Luminal potassiumGastrointestinal potassiumPotassium cation

Cation exchange within the gastrointestinal lumen to bind potassium ions and facilitate their removal from the body via fecal excretion [2][5].